Co-administration of elimusertib (50 mg/kg) and olaparib (30 mg/kg) in an ATM loss patient-derived prostate cancer model resulted in better tumor growth inhibition and longer survival of animals [56]. This evidence concerns the gene ATM and neoplasm.